News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
382,423 Results
Type
Article (25966)
Company Profile (61)
Press Release (356396)
Multimedia
Podcasts (26)
Webinars (7)
Section
Business (104301)
Career Advice (450)
Deals (16878)
Drug Delivery (51)
Drug Development (47609)
Employer Resources (47)
FDA (12272)
Job Trends (8449)
News (186003)
Policy (19435)
Tag
Academia (1752)
Accelerated approval (3)
Adcomms (8)
Allergies (74)
Alliances (26763)
ALS (58)
Alzheimer's disease (813)
Antibody-drug conjugate (ADC) (56)
Approvals (12334)
Artificial intelligence (172)
Autoimmune disease (10)
Automation (4)
Bankruptcy (142)
Best Places to Work (6899)
BIOSECURE Act (5)
Biosimilars (36)
Biotechnology (41)
Bladder cancer (59)
Brain cancer (17)
Breast cancer (203)
Cancer (1464)
Cardiovascular disease (122)
Career advice (407)
Career pathing (13)
CAR-T (72)
Cell therapy (205)
Cervical cancer (14)
Clinical research (40579)
Collaboration (451)
Compensation (138)
Complete response letters (9)
COVID-19 (1493)
CRISPR (14)
C-suite (147)
Cystic fibrosis (43)
Data (1596)
Decentralized trials (2)
Denatured (18)
Depression (31)
Diabetes (178)
Diagnostics (3528)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (13)
Drug discovery (52)
Drug pricing (55)
Drug shortages (21)
Duchenne muscular dystrophy (56)
Earnings (37106)
Editorial (22)
Employer branding (6)
Employer resources (44)
Events (51935)
Executive appointments (454)
FDA (13321)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (3)
Funding (411)
Gene editing (40)
Generative AI (10)
Gene therapy (131)
GLP-1 (407)
Government (3040)
Grass and pollen (3)
Guidances (93)
Healthcare (12190)
Huntington's disease (10)
IgA nephropathy (16)
Immunology and inflammation (42)
Indications (19)
Infectious disease (1565)
Inflammatory bowel disease (82)
Inflation Reduction Act (4)
Influenza (27)
Intellectual property (51)
Interviews (40)
IPO (7048)
IRA (19)
Job creations (1840)
Job search strategy (378)
Kidney cancer (7)
Labor market (13)
Layoffs (172)
Leadership (4)
Legal (3632)
Liver cancer (57)
Lung cancer (234)
Lymphoma (101)
Machine learning (4)
Management (17)
Manufacturing (111)
MASH (55)
Medical device (12916)
Medtech (12919)
Mergers & acquisitions (10134)
Metabolic disorders (447)
Multiple sclerosis (55)
NASH (11)
Neurodegenerative disease (50)
Neuropsychiatric disorders (9)
Neuroscience (1153)
NextGen: Class of 2025 (3933)
Non-profit (2823)
Now hiring (17)
Obesity (221)
Opinion (71)
Ovarian cancer (56)
Pain (66)
Pancreatic cancer (58)
Parkinson's disease (90)
Partnered (11)
Patents (117)
Patient recruitment (84)
Peanut (37)
People (34749)
Pharmaceutical (17)
Pharmacy benefit managers (12)
Phase I (11620)
Phase II (17568)
Phase III (14432)
Pipeline (765)
Policy (62)
Postmarket research (1668)
Preclinical (3625)
Press Release (18)
Prostate cancer (77)
Psychedelics (17)
Radiopharmaceuticals (160)
Rare diseases (186)
Real estate (2846)
Recruiting (16)
Regulatory (14241)
Reports (17)
Research institute (1607)
Resumes & cover letters (48)
Rett syndrome (2)
RNA editing (2)
RSV (20)
Schizophrenia (52)
Series A (67)
Series B (51)
Service/supplier (3)
Sickle cell disease (22)
Special edition (4)
Spinal muscular atrophy (102)
Sponsored (13)
Startups (2121)
Stomach cancer (8)
Supply chain (38)
Tariffs (14)
The Weekly (8)
Vaccines (359)
Venture capitalists (13)
Weight loss (142)
Women's health (18)
Worklife (4)
Date
Today (16)
Last 7 days (481)
Last 30 days (1548)
Last 365 days (18277)
2025 (6401)
2024 (19864)
2023 (22753)
2022 (30701)
2021 (32998)
2020 (32197)
2019 (28428)
2018 (21819)
2017 (18920)
2016 (18123)
2015 (21207)
2014 (16034)
2013 (13246)
2012 (14363)
2011 (14627)
2010 (13185)
Location
Africa (354)
Alabama (17)
Alaska (2)
Arizona (119)
Arkansas (10)
Asia (24593)
Australia (3893)
California (3160)
Canada (1248)
China (380)
Colorado (167)
Connecticut (175)
Delaware (122)
Europe (48030)
Florida (563)
Georgia (129)
Idaho (33)
Illinois (373)
India (14)
Indiana (229)
Iowa (3)
Japan (125)
Kansas (74)
Kentucky (12)
Louisiana (8)
Maine (27)
Maryland (646)
Massachusetts (2207)
Michigan (108)
Minnesota (276)
Mississippi (2)
Missouri (52)
Montana (18)
Nebraska (18)
Nevada (35)
New Hampshire (60)
New Jersey (1159)
New Mexico (9)
New York (983)
North Carolina (563)
North Dakota (4)
Northern California (1390)
Ohio (133)
Oklahoma (3)
Oregon (23)
Pennsylvania (852)
Puerto Rico (7)
Rhode Island (24)
South America (521)
South Carolina (23)
Southern California (1215)
Tennessee (79)
Texas (574)
United States (13164)
Utah (115)
Virginia (82)
Washington D.C. (42)
Washington State (232)
West Virginia (3)
Wisconsin (43)
382,423 Results for "actuated medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
April 30, 2025
·
4 min read
Press Releases
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
April 17, 2025
·
5 min read
Press Releases
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
May 8, 2025
·
11 min read
Press Releases
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2025
·
5 min read
Press Releases
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
February 6, 2025
·
4 min read
Press Releases
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
May 7, 2025
·
7 min read
Deals
Actuate Therapeutics Files Registration Statement for Initial Public Offering
Actuate Therapeutics, Inc. announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock.
May 28, 2024
·
2 min read
Press Releases
Actuate Therapeutics to be Added to Russell 2000® Index
November 27, 2024
·
4 min read
Press Releases
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
February 26, 2025
·
7 min read
Press Releases
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
January 7, 2025
·
6 min read
1 of 38,243
Next
